España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Biogen
BIIB
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$156.00
0
0.00%
Pre-Market: 5:07 PM EDT
Get Report
Comment
Biogen (BIIB) Forecast
News
Earnings
Biogen (BIIB) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Biogen (NASDAQ:BIIB) Stock
Biogen Stock (NASDAQ: BIIB)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, November 20, 2024
Biogen Unusual Options Activity For November 20
Benzinga Insights
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
Vandana Singh
Tuesday, November 19, 2024
UCB And Biogen Present Phase 3 Data On Dapiro...
Benzinga Newsdesk
Monday, November 18, 2024
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Vandana Singh
This Biogen Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Avi Kapoor
Biogen shares are trading lower after Needham...
Benzinga Newsdesk
Needham Downgrades Biogen to Hold, Maintains ...
Benzinga Newsdesk
Friday, November 15, 2024
Biogen Unusual Options Activity
Benzinga Insights
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
Avi Kapoor
Baird Maintains Outperform on Biogen, Raises ...
Benzinga Newsdesk
Wolfe Research Initiates Coverage On Biogen w...
Benzinga Newsdesk
Thursday, November 14, 2024
CHMP Recommends EU Approval For Eisai's Leqem...
Benzinga Newsdesk
Peeling Back The Layers: Exploring Biogen Through Analyst Insights
Benzinga Insights
Citigroup Initiates Coverage On Biogen with N...
Benzinga Newsdesk
Monday, November 04, 2024
Evaluating Biogen: Insights From 17 Financial Analysts
Benzinga Insights
JP Morgan Maintains Neutral on Biogen, Lowers...
Benzinga Newsdesk
Friday, November 01, 2024
Reported Earlier, Eisai And Submit LEQEMBI BL...
Benzinga Newsdesk
Thursday, October 31, 2024
Oppenheimer Maintains Outperform on Biogen, L...
Benzinga Newsdesk
Barclays Maintains Equal-Weight on Biogen, Lo...
Benzinga Newsdesk
Biogen Analysts Slash Their Forecasts After Q3 Results
Avi Kapoor
TD Cowen Maintains Buy on Biogen, Lowers Pric...
Benzinga Newsdesk
This Kraft Heinz Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Avi Kapoor
HC Wainwright & Co. Reiterates Buy on Biogen,...
Benzinga Newsdesk
Needham Reiterates Buy on Biogen, Maintains $...
Benzinga Newsdesk
Morgan Stanley Downgrades Biogen to Equal-Wei...
Benzinga Newsdesk
Reported Earlier, Eisai And Biogen Reveal Fiv...
Benzinga Newsdesk
Wednesday, October 30, 2024
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Vandana Singh
Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook
Vandana Singh
Biogen Raised Its 2024 Adjusted EPS Guidance ...
Benzinga Newsdesk
Needham Reiterates Buy on Biogen, Maintains $...
Benzinga Newsdesk
Biogen Q3 2024 Adj EPS $4.08 Beats $3.79 Esti...
Benzinga Newsdesk
Tuesday, October 29, 2024
Biogen, Neomorph Enter Research Collaboration...
Benzinga Newsdesk
Monday, October 28, 2024
Executive Vice President And CFO Michael McDo...
Benzinga Newsdesk
Reported Saturday, Biogen Revealed Results Fr...
Benzinga Newsdesk
Friday, October 25, 2024
Biogen's Tecfidera Patent Upheld By European ...
Benzinga Newsdesk
Thursday, October 24, 2024
Biogen Plans Data Presentations And Programmi...
Benzinga Newsdesk
Tuesday, October 22, 2024
Looking Into Biogen's Recent Short Interest
Benzinga Insights
Biogen Plans To Present Variety Of New Data F...
Benzinga Newsdesk
Thursday, October 17, 2024
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
Vandana Singh
BMO Capital Maintains Outperform on Biogen, L...
Benzinga Newsdesk
Wednesday, October 16, 2024
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock
Vandana Singh
Monday, October 14, 2024
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe
Vandana Singh
Friday, October 11, 2024
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
MarketBeat
Will Biogen Beat Estimates Again in Its Next Earnings Report?
Zacks
Thursday, October 10, 2024
The Latest Analyst Ratings For Biogen
Benzinga Insights
Raymond James Reinstates Market Perform on Bi...
Benzinga Newsdesk
Wednesday, October 09, 2024
Biogen Says Felzartamab Received FDA Breakthr...
Benzinga Newsdesk
Tuesday, October 08, 2024
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
Vandana Singh
Biogen Announces Detailed Results From The Ph...
Benzinga Newsdesk
Monday, October 07, 2024
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
Vandana Singh
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch